Table 1.
Patient characteristics and clinicopathological features.
| Total | PP-IPBR | SM-IPBR | P | |
|---|---|---|---|---|
| Patient N | 146 | 90 (61.65%) | 56 (38.35%) | |
| Age (years) | 43 (27–69) | 44 (28–66) | 42 (28–69) | |
| Histotype | 0.15 | |||
| - Invasive ductal | 136 (93.15%) | 83 (92.22%) | 53 (94.65%) | 0.57 |
| - Invasive lobular | 10 (6.85%) | 7 (7.78%) | 3 (5.35%) | |
| Grading | ||||
| - 1 | 0 | 0 | 0 | |
| - 2 | 30 (20.55%) | 16 (17.78%) | 14 (25.00%) | 0.29 |
| - 3 | 116 (79.45%) | 74 (82.22%) | 42 (75.00%) | |
| Ki67 (%) | 46 (1–96) | 45 (1–96) | 46 (5–80) | 0.86 |
| Stage | ||||
| - pT1 | 25 (17.12%) | 16 (17.77%) | 9 (16.08%) | 0.13 |
| - pT2 | 94 (64.38%) | 53 (58.88%) | 41 (73.22%) | |
| - pT3 | 22 (15.07%) | 16 (17.77%) | 6 (10.72%) | |
| - pT4 | 5 (3.42%) | 5 (5.55%) | 0 | |
| - pN0 | 56 (38.35%) | 33 (36.66%) | 23 (41.08%) | 0.21 |
| - pN1 | 64 (43.83%) | 37 (41.11%) | 27 (48.22%) | |
| - pN2 | 23 (15.75%) | 17 (18.88%) | 6 (10.72%) | |
| - pN3 | 3 (2.05%) | 3 (3.33%) | 0 | |
| - Multifocal | 60 (41.09%) | 33 (36.66%) | 27 (48.22%) | 0.17 |
| - pCR | 28 (19.18%) | 15 (16.67%) | 13 (23.21%) | 0.33 |
| Biological subtypes | ||||
| - Luminal-like | 61 (41.78%) | 37 (41.12%) | 24 (42.86%) | 0.059 |
| - HER2-enriched | 51 (34.94%) | 37 (41.12%) | 14 (25.00%) | |
| - Triple negative | 34 (23.29%) | 16 (17.77%) | 18 (32.15%) | |
| BRCA 1/2 | 34 (23.29%) | 20 (22.22%) | 14 (25.00%) | 0.70 |
| Postoperative treatment | ||||
| - Radiotherapy | 48 (32.87%) | 28 (31.12%) | 20 (35.72%) | 0.20 |
| - Hormone therapy | 54 (36.99%) | 31 (34.45%) | 23 (41.08%) | |
| - Chemotherapy | 8 (5.48%) | 2 (2.23%) | 6 (10.72%) |